Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
01 March 2021Website:
http://effector.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 23:52:22 GMTDividend
Analysts recommendations
Institutional Ownership
EFTR Latest News
eFFECTOR Therapeutics (EFTR) plunges on disappointing top-line results from the primary analysis of its mid-stage NSCLC study of tomivosertib, following the abandonment of the developmental program.
The average of price targets set by Wall Street analysts indicates a potential upside of 814.5% in eFFECTOR Therapeutics, Inc. (EFTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Have you ever thought about diving into penny stocks? These are the stocks that won't break the bank, typically trading for less than $5.
Are you looking for the best penny stocks to buy? You're not alone; many traders are showing a renewed interest in this exciting market.
Are you searching for some of the best penny stocks to buy now? I'm sure that if you're reading this article, that's something at the top of your mind.
This week has seen the stock market flip-flop, including the volatile world of penny stocks. Investors, especially those interested in high-risk, high-reward low-priced stocks, are attentively tracking the developments in Washington.
Penny stocks, known for their low market price and high growth potential, are an exciting segment of the financial market, particularly in sectors like technology. These low-cost shares can provide significant returns if chosen wisely, making it imperative for investors to possess tools and techniques for evaluating market sentiment.
EFFECTOR Therapeutics (NASDAQ: EFTR ) stock is taking off on Friday after the company reported positive data from a Phase 2 clinical trial. This includes interim data from its expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the management team will participate in and host 1x1 meetings at the following upcoming investor conferences:
What type of business is eFFECTOR Therapeutics?
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
What sector is eFFECTOR Therapeutics in?
eFFECTOR Therapeutics is in the Healthcare sector
What industry is eFFECTOR Therapeutics in?
eFFECTOR Therapeutics is in the Biotechnology industry
What country is eFFECTOR Therapeutics from?
eFFECTOR Therapeutics is headquartered in United States
When did eFFECTOR Therapeutics go public?
eFFECTOR Therapeutics initial public offering (IPO) was on 01 March 2021
What is eFFECTOR Therapeutics website?
https://effector.com
Is eFFECTOR Therapeutics in the S&P 500?
No, eFFECTOR Therapeutics is not included in the S&P 500 index
Is eFFECTOR Therapeutics in the NASDAQ 100?
No, eFFECTOR Therapeutics is not included in the NASDAQ 100 index
Is eFFECTOR Therapeutics in the Dow Jones?
No, eFFECTOR Therapeutics is not included in the Dow Jones index
When does eFFECTOR Therapeutics report earnings?
The next expected earnings date for eFFECTOR Therapeutics is 08 August 2024